- Home
- ARCT vs NERV Comparison
ARCT vs NERV Comparison
Compare ARCT & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | NERV |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.5M | 166.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARCT | NERV |
|---|---|---|
| Price | $11.53 | $2.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $23.80 | $10.33 |
| AVG Volume (30 Days) | ★ 750.6K | 140.3K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,031,000.00 | $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $64.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $2.41 |
| 52 Week High | $24.14 | $12.46 |
Technical Indicators
Market Signals| Indicator | ARCT | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 22.00 |
| Support Level | $6.53 | N/A |
| Resistance Level | $17.85 | $4.73 |
| Average True Range (ATR) | 1.10 | 0.24 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 0.00 | 3.64 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.